Pascal Chanu (1), Audrey Janoly-Dumenil (2), Nathalie Bleyzac (2), Jacques Bourgeois (3), Brigitte Tranchand (1) Pharmacokinetic model for vancomycin performed with sparse data on neonates
|
A. Rousseau, F. Saint-Marcoux, J. Debord, P. Marquet. Pharmacokinetics of cyclosporine in lung transplant patients with and without cystic fibrosis. A NONMEM analysis.
|
Gianluca Nucci and Roberto Gomeni Comparison of alternative models for the analysis of drug disposition profiles showing enterohepatic circulation using a population approach
|
Andreas Groth & Mikael Thomsen Markedly different predictions about insulin PharmacoDynamic (PD) measurement feasibility in healthy subjects from recently proposed IntraVenousGlucoseToleranceTest (IVGTT)-based insulin-glucose models
|
Hugo Maas, Oscar Della Pasqua, Meindert Danhof A hidden markov model for characterizing the anti-migraine action of triptans
|
K. Brendel(1), M. Legrand(2), A.M. Taburet(3), G. Baron(1), C. Goujard(4), F. Mentré(1) and the Cophar-1 study group. Population pharmacokinetic analysis of indinavir in HIV-patients treated with a stable antiretroviral therapy
|
C. Jamois(1,2,3), E. Comets(3), L. Bonhomme-Faivre(1,2) and F. Mentré(3). Pharmacokinetic analysis of paclitaxel administered per os in Swiss mice after a pre-treatment with recombinant interleukin-2 (rIL2).
|
A.Blesius (1), S. Chabaud (1), M. Cucherat (1), P. Mismetti (2), JP. Boissel (1), P.Nony (1). Potential consequences of drug non-compliance on the therapeutic / iatrogenic effects of oral anticoagulant therapy : an in silico study.
|
Nicholas H.G. Holford 1, Jogarao V.S. Gobburu,2 Diane R. Mould 3 Implications of Including and Excluding Correlation of Random Effects in Hierarchical Mixed Effects Pharmacokinetic Models
|
Xavière Panhard, France Mentré Evaluation by simulation of tests based on non-linear mixed-effects models in interaction and bioequivalence cross-over trials
|
Jan Freijer, Teun Post, Bart Ploeger, Joost DeJongh, Meindert Danhof Modelling of drug absorption as a transport-limited process
|
Hussain Mulla, Suneel Pooboni, David Jenkins, Graham Lawson, Richard Firmin, David Upton Population Pharmacokinetics of Vancomycin during Extra Corporeal Membrane Oxygenation (ECMO)
|
Philip J. Lowe (1) and William Sallas (2) Probabilistic Risk Assessment Using Integrated Preclinical-Clinical PK/PD Modelling in NONMEM
|
T. Funaki(1), Y. Gao(2), R. Wada(2), K. Nakai(1), K. Miura(1), H. Kinoshita(1) Computer-Assisted Trial Design (CATD) for PEG-IFN with Using PD Marker to Predict Efficacy
|
Lorraine D. Ralph1,2, Alison H. Thomson1,3, Nicola A. Dobbs4, Chris Twelves5 Bayesian Estimation of Epirubicin Clearance by Limited Sampling
|
Jakob Ribbing and Niclas Jonsson Power, Selection Bias And Predictive Performance Of The Population Pharmacokinetic Covariate Model
|
C. Le Guellec, F. Odoul, A. Henrot, G. Paintaud, E. Saliba, M.-C. Saux, E. Autret-Leca Population pharmacokinetics of cisapride in preterm and term neonates
|
Nguyen T. X. Q.(1), Munafo A. (1), Goggin T. (1) Population pharmacokinetic modelling of Emfilermin in healthy postmenopausal women and in women undergoing Embryo Tranfer (ET)
|
C.Tillmann, I.F. Trocóniz (#), J. Stangier, K. H. Liesenfeld, H.G. Schaefer Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR1048) in patients undergoing primary elective total hip replacement surgery.
|
K.H. Liesenfeld, C. Tillmann, I. Troconiz (#), H.G. Schaefer, J. Stangier Population pharmacodynamic analysis of dabigatran, the active form of the new oral direct thrombin inhibitor dabigatran etexilate (BIBR 1048), on the prolongation of aPTT and ECT in orthopaedic patients.
|
C. Garnett (1), K.H. Liesenfeld(2), C. Tillmann(2), I. Troconiz(3), H.G. Schaefer(2), J. Stangier(2), H. Lee (1) Clinical Trial Simulation of the Dose-Response Relationship of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Hip Replacement Patients
|
D.M. Reith (1), W. Hooper (2), M Franklin (2). Comparison of NONMEM with the Two-Stage approach for obtaining population means of the pharmacokinetic parameters of fluoxetine
|
Sophie Glatt, Mauro Buraglio, Eliane Fuseau Population Pharmacokinetics of onercept in healthy subjects.
|
Bruce Green(1), John Atherton(2), Justin Westhuyzen(2),Leeanne Kluver(2),David Saltisi(2) Development of a dosing strategy for enoxaparin in patients with renal impairment using a population pharmacokinetic approach
|
Daniël M. Jonker (1,2), Rob A. Voskuyl (1,2) and Meindert Danhof (1) Population pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination
|
Milly E de Jonge(1), Alwin DR Huitema(1), Sjoerd Rodenhuis(2) and Jos H Beijnen(1). Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.
|
Christoffer W. Tornøe(1), Henrik Agersø(1), E. Niclas Jonsson(2), Henrik Madsen(3), and Henrik A. Nielsen(3) Non-Linear Mixed-Effects Models in NLME with Differential Equations
|
I. Gueorguieva, L. Aarons, T. Rodgers and M. Rowland D-Optimal Design for Multivariate Response: Prospective Planning of a Beta-blocker Study in Rat Involving Cassette Dosing
|
S. Gisbert, I. Gueorguieva, L. Aarons and M. Rowland Incorporating Variability in WBPBPK Models: Application to Three Benzodiazepines with Extrapolation from Rat to Man
|
In-Sun Nam and Leon Aarons Multiple Imputation of Serum Creatinine
|
K.Ogungbenro and L. Aarons Sample Size Calculation based on Confidence interval for Pharmacokinetic Studies
|
Robert Bies (1,2), Mark E. Sale (3), Bruce G. Pollock (1,2) Comparing binary tree and automated machine learning covariate search strategies
|
Gudrun Würthwein (1), Georg Hempel (2), Felice C. Adler-Shohet (3), Jay M. Lieberman (3), Thomas J. Walsh (4), and Andreas H. Groll (2) Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates
|
Y Bourhis (1), A Iliadis (2), C Lucas (3), AB Depouilly (3), C Laveille (3), B Tranchand (1) Population Pharmacokinetic Study of Fotemustine
|
Y. Merlé (1,2), J.M. Tréluyer (2,3), E. Rey (3), J. Dimet (3), G. Leleu (4), S. Blanche (5). Nonparametric population analysis of stavudine pharmacokinetic data in neonates, infants, children and adults
|
Sophie Callies 2, Dinesh P de Alwis 1, Michael Burgess 1, and Leon Aarons 2 Pharmacokinetics of Daunorubicin and its metabolite Daunorubicinol in the absence and presence of a potent P-gp inhibitor, Zosuquidar.3HCl (LY335979).
|
M. Simeoni(1), F. Fiorentini (2), M. Germani(2), I. Poggesi(2), M. Rocchetti (2) Application of population approaches in pharmaco-toxicological studies
|
P. Magni(1), R. Bellazzi (1), G. De Nicolao(1), M. Simeoni(1), M. Germani(2), I. Poggesi(2), M. Rocchetti (2) A Bayesian approach to non-parametric AUC estimation in population studies
|
Leonid Gibiansky (1), Michel MRF Struys (2), Ekaterina Gibiansky (3) Simultaneous Population Pharmacokinetic Model of AQUAVAN™ And AQUAVAN™-Derived Propofol
|
Ekaterina Gibiansky (1), Michel MRF Struys (2), Leonid Gibiansky (3) Bispectral Index of AQUAVAN™-Derived Propofol: Population PK/PD Modeling and Application to an Effect - Controlled Trial
|
Monica Rodriguez(1), Nerea Leal(1), Rosario Calvo(1), Elena Suarez(1), Ignacio Ortega(1), John C Lukas(2) Influence of high levels of alpha-1-acid glycoprotein in the pharmacokinetics and the analgesic effect of methadone in the rat: A population approach
|
Nerea Leal(1), Monica Rodriguez(1), Rosario Calvo(1), Fatima Agrad(1), Leire de la Fuente(2), Elena Suarez(1), John C Lukas(3) Altered effect and pharmacokinetics of propofol in rats with experimental diabetes mellitus
|
Robert Leary [1], Roger Jelliffe [2], Alan Schumitzky[2], Michael Van Guilder [2] Improved Computational Methods for Statistically Consistent and Efficient PK/PD Population Analysis
|
T. Waterhouse (1), J. Eccleston (1), S. Duffull (2) Optimal Designs For Parameter Estimation And Model Discrimination
|
An Vermeulen Ph.D., Vladimir Piotrovsky Ph.D. Modeling the longitudinal concentration-response data after i.m. administration of Risperdal CONSTATM in psychotic patients of different phenotypes
|
Vladimir Piotrovsky Population PK-PD analysis of cardiovascular effects of non-cardiovascular drugs with the emphasis on QT prolongation
|
Kristin Karlsson, Mats O. Karlsson, Anders Grahnén and E. Niclas Jonsson Randomized dose ranging trials; assessment of statistical power for various design and analysis strategies
|
Daren J Austin and Ann Allen Meta analysis and clinical trial simulation in drug development.
|
A. Lemenuel-Diot(1), N.frey(2), C. Laveille(2), R. Jochemsen(2), A. Mallet(1) Comparison between Gauss Hermite quadrature and NONMEM on the ability to detect subpopulations
|
Kristin Cecilie Carlsson(1), Heidi Hansen(1), Roger Jelliffe(2), Nils Ove Hoem(3). Establishing a tool for individualised dosing of gabapentin - The use of a non-parametric population kinetics model in the MM-USCPACK software, a new tool for clinical dosage optimization.
|
Xuejun Chen, Suresh Mallikaarjun, Steven L. Bramer Comparison of different approaches for the analysis of drug exhibiting nonlinearity of Cmax to increasing doses
|
Karin Tunblad, Margareta Hammarlund-Udenaes and Niclas Jonsson An integrated model for data from a microdialysis experiment
|
Sandra A.G. Visser(1), Susanna Pozarek(1), Tomas Forsberg(2), Johan Gabrielsson(1). Modelling of the tolerance, rebound and carry-over phenomena observed in clomethiazole-induced hypothermic effects in rats.
|
Stefano Zamuner and Roberto Gomeni Impact of slow receptor binding kinetics and change in Cerebral Blood Flow in receptor occupancy estimation with PET experiments. A simulation study
|
A. Bertoldo, G. Sparacino, C. Cobelli Population approaches for quantitative PET imaging
|
Ulrika S.H. Simonsson, Thomas Senderovitz and Mats O. Karlsson Population PK/PD Modeling of Testosterone (T), LH and Dihydrotestosterone (DHT) Response to Single SC Degarelix in Male Volunteers
|
Sabrina Salhi and Roberto Gomeni Population Whole Body Physiologically based Pharmacokinetic/Pharmacodynamic modelling in drug development: Impact of input parameters variability and incertainty on pharmacodynamic response
|
J Aluri, B Zussman, J Sidhu, B Patel and D Boyle Cilomilast (Ariflo): Population pharmacokinetic modeling and validation in COPD patients.
|
B Mc Hugh (1), R Gieschke (1), M Karlsson (2) Population Pharmacodynamic Analysis of Glucose and Insulin levels Evaluated with a Hot Glucose Minimal Model, a Total Glucose Minimal Model, and an Insulin Minimal Model
|
Zamacona MK, Gomeni R Influence of study design and interindividual variability on In Vitro - In Vivo Correlation evaluation
|
Dymphy Huntjens, Magret Blom-Roosemalen, David Spalding, Meindert Danhof and Oscar Della Pasqua Modelling of biomarker response of naproxen in rats and humans
|
L. Labbé (1), S.M. Hammer (2), J.W. Mellors (3), S. Rosenkranz (4), L.B. Sheiner (1), and the ACTG 398 study team A Markov Model For The Effect Of Covariates Including Drug Adherence On Longitudinal Viral Response In HIV Patients
|
Delphine Martin, Roeline Jochemsen , Christian Laveille and Nicolas Frey Combined-PK-Analysis of a new compound exhibiting highly variable plasma profiles due to first pass metabolism
|
Sunny Chapel, PhD, Jeffrey S. Barrett, PhD, Marc Pfister, MD Modeling & Simulation Approach to Discriminate True Food Effects: Comparison with Standard Noncompartmental Methods
|
Sy SK(1,2,3), Pieniaszek HJ(3,4), Kornhauser DM(3), Davidson AF(3), Jiao Q(3), Cain V(3,5), Martin DE(3,6) Pharmacodynamic drug interaction of roxifiban during CYP induction and inhibition
|
Sandström M (1), Lindman H (2) , Nygren P (2), and Karlsson MO (1) Population Analysis of the Pharmacokinetics and the Haematological Toxicity of the Fluorouracil-Epirubicin-Cyclophosphamide Regimen in Breast Cancer Patients
|
A.C. Hooker, M. Dodds, and P. Vicini Simultaneous Population D-Optimal Designs of Pharmacokinetic-Pharmacodynamic Experiments
|
MJ. Garrido(1), JM. Cendrós(2), IF. Trocóniz(1), C. Segura(1), C. Peraire(2), R. Obach(2) Population pharmacokinetic/pharmacodynamic modelling of the haematological effects of the new anticancer drug diflomotecan: A combined analysis from the first two phase I studies
|
Eugène Cox (1), Henrik Agerso (2), Thomas Senderovitz(2). A Population Pharmacokinetic-Pharmacodynamic Model For Count Data: Application to the Effect of Atosiban on Uterine Activity in Preterm Labor Patients
|
P. Girard, L. Claret, W. Ebling and S.T. Forgue, M. Heathman, A. Ghosh, C.T. Benson Evaluation Of An Osteoporosis Biomarker Model For Simulation Using Posterior Predictive Check Technique
|